Arbutus Biopharma
Develops chronic HBV therapies while monetizing legacy lipid-nanoparticle IP.
$5.09
After-hours close+0.04 (+0.74%)
At close$5.06(−2.22%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.02 | — | — |
| Aug 2026 | −$0.02 | −$0.03 | −50.0% |
| Aug 2026 | −$0.02 | −$0.03 | −50.0% |
| May 2026 | −$0.03 | $0.87 | +3,000.0% |
| Mar 2026 | −$0.04 | −$0.01 | +71.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | −$0.02 | — | — | $1.0M | — | — |
| Aug 12, 2026 | −$0.02 | −$0.03 | −50.0% | $700.0K | $1.0M | +44.9% |
| Aug 11, 2026 | −$0.02 | −$0.03 | −50.0% | $700.0K | $1.0M | +44.9% |
| May 13, 2026 | −$0.03 | $0.87 | +3,000.0% | $750.0K | $179.1M | +23,783.5% |
| Mar 23, 2026 | −$0.04 | −$0.01 | +71.5% | $614.5K | $1.1M | +71.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Nov 13, 2025 | ||||||
| Aug 6, 2025 | ||||||
| May 14, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 1, 2024 | ||||||
| May 2, 2024 | ||||||
| Feb 29, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 4, 2023 | ||||||
| Mar 2, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 5, 2022 | ||||||
| Mar 3, 2022 | ||||||
| Nov 4, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 5, 2021 | ||||||
| Mar 4, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 7, 2020 | ||||||
| May 11, 2020 | ||||||
| Mar 5, 2020 | ||||||
| Nov 6, 2019 | ||||||
| Aug 5, 2019 | ||||||
| May 6, 2019 | ||||||
| Mar 7, 2019 | ||||||
| Nov 7, 2018 | ||||||
| Aug 2, 2018 | ||||||
| May 3, 2018 | ||||||
| Mar 14, 2018 | ||||||
| Nov 2, 2017 | ||||||
| Aug 3, 2017 | ||||||
| May 4, 2017 | ||||||
| Mar 21, 2017 | ||||||
| Nov 3, 2016 | ||||||
| Aug 4, 2016 | ||||||
| May 4, 2016 | ||||||
| Mar 9, 2016 | ||||||
| Nov 5, 2015 | ||||||